Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenming Shun

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|December 13, 2002
Stopping boundaries adjusted for sample size reestimation and negative stopZhenming Shun
Statistics in Medicine|July 10, 2007
Interim treatment selection using the normal approximation approach in clinical trialsZhenming Shun, K K Gordon Lan, Yuhwen Soo
Statistics in Medicine|November 30, 2004
Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness--one larger vs two smaller pivotal studiesZhenming Shun, Eric Chi, Sylvain Durrleman, et al.
Journal of Biopharmaceutical Statistics|March 15, 2003
Dunnett's many-to-one test and least square meansZhenming Shun, Arthur Silverberg, C K Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Reply to M. Horiguchi et alMario A Eisenberger, Wenping Zhang, Zhenming Shun, et al.
Journal of Biopharmaceutical Statistics|February 4, 2015
A note on sequential monitoring of select-the-winner designK K Gordon Lan, Fei Chen, Bob Zhong, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancerAlexander Meisel, Ronald de Wit, Stephane Oudard, et al.
Cancer|October 16, 2013
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm studyWilliam P Tew, Nicoletta Colombo, Isabelle Ray-Coquard, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|December 13, 2002
Stopping boundaries adjusted for sample size reestimation and negative stopZhenming Shun
Statistics in Medicine|July 10, 2007
Interim treatment selection using the normal approximation approach in clinical trialsZhenming Shun, K K Gordon Lan, Yuhwen Soo
Statistics in Medicine|November 30, 2004
Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness--one larger vs two smaller pivotal studiesZhenming Shun, Eric Chi, Sylvain Durrleman, et al.
Journal of Biopharmaceutical Statistics|March 15, 2003
Dunnett's many-to-one test and least square meansZhenming Shun, Arthur Silverberg, C K Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Reply to M. Horiguchi et alMario A Eisenberger, Wenping Zhang, Zhenming Shun, et al.
Journal of Biopharmaceutical Statistics|February 4, 2015
A note on sequential monitoring of select-the-winner designK K Gordon Lan, Fei Chen, Bob Zhong, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancerAlexander Meisel, Ronald de Wit, Stephane Oudard, et al.
Cancer|October 16, 2013
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm studyWilliam P Tew, Nicoletta Colombo, Isabelle Ray-Coquard, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.
Pageof 1